Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ECYT's Cash-to-Debt is ranked higher than
82% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:ECYT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ECYT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.95
NAS:ECYT's Equity-to-Asset is ranked higher than
96% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ECYT: 0.95 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ECYT' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.94  Med: 0.95 Max: 0.97
Current: 0.95
-2.94
0.97
Interest Coverage No Debt
NAS:ECYT's Interest Coverage is ranked higher than
76% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ECYT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ECYT' s Interest Coverage Range Over the Past 10 Years
Min: 5027  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 2.78
Beneish M-Score: -0.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -60954.17
NAS:ECYT's Operating Margin % is ranked lower than
98% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:ECYT: -60954.17 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ECYT' s Operating Margin % Range Over the Past 10 Years
Min: -63885.71  Med: -2023.2 Max: 7.15
Current: -60954.17
-63885.71
7.15
Net Margin % -59730.56
NAS:ECYT's Net Margin % is ranked lower than
98% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:ECYT: -59730.56 )
Ranked among companies with meaningful Net Margin % only.
NAS:ECYT' s Net Margin % Range Over the Past 10 Years
Min: -62697.14  Med: -2132.74 Max: 7.76
Current: -59730.56
-62697.14
7.76
ROE % -31.60
NAS:ECYT's ROE % is ranked higher than
54% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:ECYT: -31.60 )
Ranked among companies with meaningful ROE % only.
NAS:ECYT' s ROE % Range Over the Past 10 Years
Min: -492.46  Med: -20.57 Max: 3.72
Current: -31.6
-492.46
3.72
ROA % -30.32
NAS:ECYT's ROA % is ranked higher than
50% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:ECYT: -30.32 )
Ranked among companies with meaningful ROA % only.
NAS:ECYT' s ROA % Range Over the Past 10 Years
Min: -91.6  Med: -27.27 Max: 2.91
Current: -30.32
-91.6
2.91
ROC (Joel Greenblatt) % -1397.23
NAS:ECYT's ROC (Joel Greenblatt) % is ranked lower than
66% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:ECYT: -1397.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ECYT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3911.11  Med: -1354.54 Max: 128.73
Current: -1397.23
-3911.11
128.73
3-Year Revenue Growth Rate -89.60
NAS:ECYT's 3-Year Revenue Growth Rate is ranked lower than
92% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ECYT: -89.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ECYT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -88.45 Max: 522.1
Current: -89.6
0
522.1
3-Year EBITDA Growth Rate 28.40
NAS:ECYT's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:ECYT: 28.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ECYT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -70.1 Max: 29.1
Current: 28.4
0
29.1
3-Year EPS without NRI Growth Rate 27.70
NAS:ECYT's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:ECYT: 27.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ECYT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -70.5 Max: 27.7
Current: 27.7
0
27.7
GuruFocus has detected 4 Warning Signs with Endocyte Inc $NAS:ECYT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ECYT's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ECYT Guru Trades in Q3 2016

Jim Simons 189,000 sh (New)
» More
Q4 2016

ECYT Guru Trades in Q4 2016

Jim Simons 50,100 sh (-73.49%)
» More
Q1 2017

ECYT Guru Trades in Q1 2017

Jim Simons 192,561 sh (+284.35%)
» More
Q2 2017

ECYT Guru Trades in Q2 2017

Jim Simons 120,724 sh (-37.31%)
» More
» Details

Insider Trades

Latest Guru Trades with ECYT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:NBY, NAS:PLXP, NAS:CHMA, NAS:FLKS, NAS:TCON, NAS:ADMA, OTCPK:ANTB, NAS:AGTC, OTCPK:NWBO, NAS:INFI, AMEX:RNN, OTCPK:ORGS, NAS:AQB, NAS:LPTX, NAS:EGLT, OTCPK:PNTV, NAS:CYTR, OTCPK:PMCB, NAS:KALV, NAS:KMPH » details
Traded in other countries:9EY.Germany,
Headquarter Location:USA
Endocyte Inc is a biopharmaceutical company. It is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases.

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases using precision medicine. Precision medicine is a medical discipline seeking to treat diseased cells with minimal impact on healthy cells. The company uses its proprietary technology to create novel small-molecule drug conjugates and companion imaging agents. The company's therapeutic areas are non-small cell lung, breast, colorectal, kidney, endometrial, prostate, and ovarian cancers; solid tumors; polycystic kidney disease; and inflammation.

Ratios

vs
industry
vs
history
PB Ratio 0.50
ECYT's PB Ratio is ranked higher than
98% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ECYT: 0.50 )
Ranked among companies with meaningful PB Ratio only.
ECYT' s PB Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.26 Max: 11.64
Current: 0.5
0.44
11.64
EV-to-EBIT 1.35
ECYT's EV-to-EBIT is ranked higher than
88% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ECYT: 1.35 )
Ranked among companies with meaningful EV-to-EBIT only.
ECYT' s EV-to-EBIT Range Over the Past 10 Years
Min: -50.6  Med: -0.7 Max: 30.6
Current: 1.35
-50.6
30.6
EV-to-EBITDA 1.38
ECYT's EV-to-EBITDA is ranked higher than
89% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ECYT: 1.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
ECYT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.6  Med: -0.8 Max: 26.1
Current: 1.38
-57.6
26.1
EV-to-Revenue -822.12
ECYT's EV-to-Revenue is ranked lower than
99.99% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ECYT: -822.12 )
Ranked among companies with meaningful EV-to-Revenue only.
ECYT' s EV-to-Revenue Range Over the Past 10 Years
Min: -930.1  Med: 4.1 Max: 1459.5
Current: -822.12
-930.1
1459.5
Current Ratio 22.77
ECYT's Current Ratio is ranked higher than
96% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ECYT: 22.77 )
Ranked among companies with meaningful Current Ratio only.
ECYT' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 10.09 Max: 38
Current: 22.77
1.26
38
Quick Ratio 22.77
ECYT's Quick Ratio is ranked higher than
96% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ECYT: 22.77 )
Ranked among companies with meaningful Quick Ratio only.
ECYT' s Quick Ratio Range Over the Past 10 Years
Min: 1.26  Med: 10.09 Max: 38
Current: 22.77
1.26
38
Days Sales Outstanding 40.56
ECYT's Days Sales Outstanding is ranked higher than
81% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ECYT: 40.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
ECYT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.66  Med: 46.93 Max: 286.79
Current: 40.56
3.66
286.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.40
ECYT's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ECYT: -5.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ECYT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -240.4  Med: -5.35 Max: 0
Current: -5.4
-240.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.52
ECYT's Price-to-Net-Cash is ranked higher than
99% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ECYT: 0.52 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ECYT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.52  Med: 2.19 Max: 32.02
Current: 0.52
0.52
32.02
Price-to-Net-Current-Asset-Value 0.52
ECYT's Price-to-Net-Current-Asset-Value is ranked higher than
99% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ECYT: 0.52 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ECYT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.52  Med: 2.13 Max: 17.28
Current: 0.52
0.52
17.28
Price-to-Tangible-Book 0.51
ECYT's Price-to-Tangible-Book is ranked higher than
99% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ECYT: 0.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ECYT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.5  Med: 1.31 Max: 9.83
Current: 0.51
0.5
9.83
Price-to-Median-PS-Value 34.75
ECYT's Price-to-Median-PS-Value is ranked lower than
99% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ECYT: 34.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ECYT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 1 Max: 114.5
Current: 34.75
0.07
114.5
Earnings Yield (Greenblatt) % 74.13
ECYT's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ECYT: 74.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ECYT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19263  Med: -3 Max: 2545.1
Current: 74.13
-19263
2545.1

More Statistics

Revenue (TTM) (Mil) $0.07
EPS (TTM) $ -1.02
Beta1.49
Short Percentage of Float3.14%
52-Week Range $1.17 - 3.49
Shares Outstanding (Mil)42.58

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.93 -0.72 -1.31
EPS without NRI ($) -0.93 -0.72 -1.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ECYT

Headlines

Articles On GuruFocus.com
Endocyte to Present at the 2017 Cantor Global Healthcare Conference Sep 19 2017 
Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytoki Sep 06 2017 
Endocyte Announces Presentation at the European Society for Medical Oncology (ESMO) Sep 05 2017 
Endocyte Announces Presentations at the 254th American Chemical Society National Meeting & Expositio Aug 16 2017 
Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update Aug 08 2017 
Endocyte Announces Second Quarter 2017 Earnings Conference Call Aug 01 2017 
Endocyte Announces Clinical Updates for EC1456 and EC1169 Jun 02 2017 
Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Onco May 26 2017 
Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update May 10 2017 
Endocyte Announces First Quarter 2017 Earnings Conference Call May 03 2017 

More From Other Websites
Endocyte to Present at the 2017 Cantor Global Healthcare Conference Sep 19 2017
Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage... Sep 06 2017
Endocyte Announces Presentation at the European Society for Medical Oncology (ESMO) Sep 05 2017
ETFs with exposure to Endocyte, Inc. : August 31, 2017 Aug 31 2017
Endocyte, Inc. :ECYT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Aug 24 2017
Edited Transcript of ECYT earnings conference call or presentation 8-Aug-17 8:30pm GMT Aug 16 2017
Endocyte Announces Presentations at the 254th American Chemical Society National Meeting &... Aug 16 2017
Endocyte reports 2Q loss Aug 10 2017
Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss Aug 09 2017
Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update Aug 08 2017
Investor Network: Endocyte, Inc. to Host Earnings Call Aug 08 2017
Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat Aug 04 2017
Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View Aug 04 2017
Endocyte Announces Second Quarter 2017 Earnings Conference Call Aug 01 2017
What's in Store for Endocyte (ECYT) this Earnings Season? Jul 26 2017
Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform Jul 13 2017
ETFs with exposure to Endocyte, Inc. : June 20, 2017 Jun 20 2017
Why Is Endocyte (ECYT) Down 37.9% Since the Last Earnings Report? Jun 14 2017
Endocyte, Inc. :ECYT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Jun 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}